Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darbepoetin alfa
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Darbepoetin alfa is a recombinant form of human erythropoietin designed to stimulate the production of red blood cells. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells and differs from endogenous erythropoietin by having additional carbohydrate chains that enhance its half-life. Darbepoetin alfa acts as an erythropoiesis-stimulating agent (ESA), binding to and activating the erythropoietin receptor on progenitor cells in the bone marrow to increase red blood cell production. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in patients with non-myeloid malignancies[1][2][3][4][5][6][8].
- Brand names
- AranespAranesp SureClickAranesp Albumin FreeAranesp SingleJect
- Other names
- darbepoetin alfadarbepoetindarbepoetina alfa
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on darbepoetin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darbepoetin alfa.